These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 26780119)

  • 1. Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic study in age-related macular degeneration assessed with swept-source optical coherence tomography.
    Teper SJ; Nowinska A; Pilat J; Wylegala E
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():108-113. PubMed ID: 26780119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.
    Park UC; Shin JY; McCarthy LC; Kim SJ; Park JH; Chung H; Yu HG
    Mol Vis; 2014; 20():1680-94. PubMed ID: 25558172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.
    Lotery AJ; Gibson J; Cree AJ; Downes SM; Harding SP; Rogers CA; Reeves BC; Ennis S; Chakravarthy U;
    Ophthalmology; 2013 Dec; 120(12):2637-2643. PubMed ID: 24070809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
    Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
    Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA; Ramachandran V; Ismail P; Mohd Isa H; Chan YM; Ngah NF; Md Bakri N; Ching SM; Hoo FK; Wan Sulaiman WA; Inche Mat LN; Hazmi Mohamed M
    Bosn J Basic Med Sci; 2018 Aug; 18(3):260-267. PubMed ID: 29579408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy for polypoidal choroidal vasculopathy.
    Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH
    Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
    Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
    Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.
    Brantley MA; Fang AM; King JM; Tewari A; Kymes SM; Shiels A
    Ophthalmology; 2007 Dec; 114(12):2168-73. PubMed ID: 18054635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
    Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
    Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
    Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration.
    Feng X; Xiao J; Longville B; Tan AX; Wu XN; Cooper MN; McAllister IL; Isaacs T; Palmer LJ; Constable IJ
    Ophthalmology; 2009 Oct; 116(10):1908-12.e1. PubMed ID: 19692124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Bessho H; Honda S; Kondo N; Negi A
    Mol Vis; 2011 Apr; 17():977-82. PubMed ID: 21541271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment.
    Goverdhan SV; Hannan S; Newsom RB; Luff AJ; Griffiths H; Lotery AJ
    Eye (Lond); 2008 Jun; 22(6):849-54. PubMed ID: 17464302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal Vessel Functionality Is Linked With ARMS2 A69S and CFH Y402H Polymorphisms and Choroidal Status in AMD Patients.
    Krytkowska E; Ulanczyk Z; Grabowicz A; Mozolewska-Piotrowska K; Safranow K; Palucha A; Krawczyk M; Sikora P; Matczynska E; Stahl A; Machalinski B; Machalinska A
    Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):30. PubMed ID: 33900362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
    Ladewig MS; Karl SE; Hamelmann V; Helb HM; Scholl HP; Holz FG; Eter N
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thickness of retina and choroid in the elderly population and its association with Complement Factor H polymorphism: KLoSHA Eye study.
    Ryoo NK; Ahn SJ; Park KH; Ahn J; Seo J; Han JW; Kim KW; Woo SJ
    PLoS One; 2018; 13(12):e0209276. PubMed ID: 30596689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration.
    Tsuchihashi T; Mori K; Horie-Inoue K; Gehlbach PL; Kabasawa S; Takita H; Ueyama K; Okazaki Y; Inoue S; Awata T; Katayama S; Yoneya S
    Ophthalmology; 2011 Jan; 118(1):93-100. PubMed ID: 20678803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year efficacy of "rescue photodynamic therapy" for patients with typical age-related macular degeneration, polypoidal choroidal vasculopathy, and pachychoroid neovasculopathy refractory to anti-vascular endothelial growth factor therapy.
    Wada I; Shiose S; Ishikawa K; Kano K; Notomi S; Mori K; Akiyama M; Nakao S; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):2029-2036. PubMed ID: 35038016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.